Dr. Daniel Furst's research interests are in the clinical pharmacology of drugs used to treat rheumatic and autoimmune diseases, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs and biological modifiers. He also has an ongoing interest in scleroderma's pathogenesis, measurement and treatment.
Furst has published more than 300 articles and 10 books. He has served or is serving on the editorial board of Inpharma, Clinical Drug Invest, Drugs, The Journal of Clinical Rheumatology and The Journal of Rheumatology. Additionally, he is an editorial reviewer for professional publications including Arthritis & Rheumatism, New England Journal of Medicine, Journal of Clinical Investigation, Pharmacotherapy and Journal of Rheumatology.